Clinic Roundup

Keryx Biopharmaceuticals Inc., of New York, said the independent data safety monitoring board for the firm's pivotal Phase III X-PECT (Xeloda + Perifosine Evaluation in Colorectal cancer Treatment) study of perifosine (KRX-0401) in refractory advanced colorectal cancer completed a pre-specified interim safety and futility analysis and recommended the trial continue as planned. The study has completed enrollment, with more than 465 patients, and is being conducted under a special protocol assessment.